SCHEMBL3868334

SCHEMBL3868334

CC(C)C(O)CCCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.46
TRPA1 O75762 1/20 0.46
SPHK1 Q9NYA1 2/20 0.39
LMNA P02545 3/20 0.37
CYP2D6 P10635 2/20 0.37
GMNN O75496 1/20 0.37
POLB P06746 1/20 0.37
THPO P40225 1/20 0.37
MTOR P42345 1/20 0.37
BLM P54132 1/20 0.37
KDM4E B2RXH2 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
CETP P11597 1/20 0.37
HTT P42858 1/20 0.37
UBE2N P61088 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28335927 0.97 TRPV1 (0.50) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL15509789 0.97 TRPV1 (0.50) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL6169557 0.97 TRPV1 (0.50) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL28870509 0.97 TRPV1 (0.44) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL8532467 0.92
SCHEMBL31501273 0.85 TRPV1 (0.60) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL8412963 0.85 PTPN1 (0.39) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL15484265 0.83 TRPV1 (0.46) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL5127737 0.82 TRPV1 (0.48) TRPV1TRPA1SPHK1LMNACYP2D6
SCHEMBL3399170 0.82 TRPV1 (0.41) TRPV1TRPA1SPHK1LMNACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2816096-B1 METHOD AND APPARATUS FOR STORING EXCESS ENERGY EVONIK OPERATIONS GMBH (DE) 2021-05-12 EP claimed
EP-2816096-A1 Method for storing excess energy Evonik Industries AG (DE) 2014-12-24 EP claimed
WO-2004106281-A1 CRYSTALLINE GABAPENTIN RANBAXY LABORATORIES LIMITED (IN) 2004-12-09 WO claimed
CN-1110541-C Concentrated water-dispersible stable fiber softener compositions PROCTER & GAMBLE (US) 2003-06-04 CN claimed
CN-1219953-A Fabric softening compound/composition PROCTER & GAMBLE (US) 1999-06-16 CN claimed
CN-1196081-A Concentrated, water dispersible, stable, fabric softening compositions PROCTER & GAMBLE (US) 1998-10-14 CN claimed
CN-1195369-A Concentrated and stable fabric softening compositions PROCTER & GAMBLE (US) 1998-10-07 CN claimed
EP-0842250-A1 CONCENTRATED, STABLE FABRIC SOFTENING COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1998-05-20 EP claimed
EP-0839179-A1 CONCENTRATED, WATER DISPERSIBLE, STABLE, FABRIC SOFTENING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1998-05-06 EP claimed
WO-1998017756-A1 CONCENTRATED FABRIC SOFTENING COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1998-04-30 WO claimed
WO-1997003170-A1 CONCENTRATED, WATER DISPERSIBLE, STABLE, FABRIC SOFTENING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1997-01-30 WO claimed
WO-1997003169-A1 CONCENTRATED, STABLE FABRIC SOFTENING COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1997-01-30 WO claimed
US-12522619-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2026-01-13 US disclosed
EP-4463462-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2024-11-20 EP disclosed
CN-118715231-A Complement factor inhibitors and uses thereof 安尼艾克松股份有限公司 2024-09-27 CN disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-4931537-A CURABLE EPOXY SYSTEMS; HYDROXY-FUNCTIONAL GLYCIDAMIDES FROM AMINO RESINS; SOLVENT, WEATHER RESISTANT MONSANTO COMPANY (US) 1990-06-05 US disclosed
US-4931536-A PRECURSORS FOR EPOXIDIZED ANINO RESINS; METHYLOLATING CYCLIC UREA OR MELAMINE COMPONENTS, ETHERIFICATION, ACRYLAMIDATION, TRANSETHERIFICATION, EPOXIDATION MONSANTO COMPANY (US) 1990-06-05 US disclosed
EP-0345240-A2 Hydroxy functional acrylamidomethyl amino resins and hydroxy functional glycidamidomethyl amino resins MONSANTO COMPANY (US) 1989-12-06 EP disclosed
EP-0344144-A2 Polyglycidamide coating compositions MONSANTO COMPANY (US) 1989-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 TRPV1 3867/4885TRPA1 2579/4885SPHK1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.